Purchase this article with an account.
Atsushi Ishikawa, Yutaka Imamura, Moe Mita-Takahashi, Rieko Higashida, Yorihisa Tsutsumi, Yoshikazu Ichikawa, Masahiro Ishida; Intravitreal Injection of Bevacizumab for Macula Edema Secondary to Central Retinal Vein Occlusion: Efficacy at 1 Day after Injection. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5846.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the visual and anatomical outcome in eyes with macular edema secondary to central retinal vein occlusion (CRVO) at 1 day after injection of intravitreal bevacizumab.
A retrospective, consecutive case series identified 20 consecutive patients with CRVO undergoing intravitreal injection of bevacizumab. Optical coherence tomography images were taken at the day of injection and 1-day after injection. Retinal thickness at fovea, height of serous retinal detachment and visual acuity were monitored before and after injection.
The mean age of patients was 67.8 years old (6 females). Retinal thickness at fovea was 726 ± 281 µm before injection and was 440 ± 264 µm at 1 day after injection. (Student t test, P=0.0020) Height of retinal detachment was 221±215 µm before injection and 139±176 µm 1-day after injection. (P=0.264) Visual acuity (logMAR) was 0.762±0.477 before injection and 0.713±0.436 at 1 day after injection. (P=0.732)
Rapid resolution of intraretinal fluids was observed in CRVO, however significant improvement of vision was not observed at 1 day after injection.
This PDF is available to Subscribers Only